Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D Vincent

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Advances in Cancer Research|September 20, 2011
Cancer: beyond speciationMark D Vincent
Frontiers in Oncology|December 25, 2014
Promising targets and current clinical trials in metastatic squamous cell lung cancerMark D Vincent
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|August 24, 2017
Cancer: Towards a general theory of the target: All successful cancer therapies, actual or potential, are reducible to either (or both) of two fundamental strategiesMark D Vincent
Evolution; International Journal of Organic Evolution|January 12, 2010
The animal within: carcinogenesis and the clonal evolution of cancer cells are speciation events sensu strictoMark D Vincent
The Lancet. Oncology|March 6, 2009
The price function of toxicityMark D Vincent, George Dranitsaris
Supportive Cancer Therapy|July 18, 2008
Balancing risk and benefit for first-line treatment of metastatic colorectal cancer: a graphic communication tool for patients and physiciansMichael S Sanatani, Mark D Vincent
The Journal of Pharmacology and Experimental Therapeutics|October 25, 2017
Synergistic Antiproliferative Activity of the RAD51 Inhibitor IBR2 with Inhibitors of Receptor Tyrosine Kinases and Microtubule ProteinPeter J Ferguson, Mark D Vincent, James Koropatnick
Canadian Respiratory Journal|April 25, 2003
Primary chemoradiation as definitive treatment for unresectable cancer of the tracheaGregory M M Videtic, Carolyn Campbell, Mark D Vincent
Expert Review of Pharmacoeconomics & Outcomes Research|April 24, 2018
Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugsGeorge Dranitsaris, Xiaofu Zhu, Georges Adunlin, et al.
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|July 22, 2014
Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic modelCharles H Lineweaver, Paul C W Davies, Mark D Vincent
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Advances in Cancer Research|September 20, 2011
Cancer: beyond speciationMark D Vincent
Frontiers in Oncology|December 25, 2014
Promising targets and current clinical trials in metastatic squamous cell lung cancerMark D Vincent
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|August 24, 2017
Cancer: Towards a general theory of the target: All successful cancer therapies, actual or potential, are reducible to either (or both) of two fundamental strategiesMark D Vincent
Evolution; International Journal of Organic Evolution|January 12, 2010
The animal within: carcinogenesis and the clonal evolution of cancer cells are speciation events sensu strictoMark D Vincent
The Lancet. Oncology|March 6, 2009
The price function of toxicityMark D Vincent, George Dranitsaris
Supportive Cancer Therapy|July 18, 2008
Balancing risk and benefit for first-line treatment of metastatic colorectal cancer: a graphic communication tool for patients and physiciansMichael S Sanatani, Mark D Vincent
The Journal of Pharmacology and Experimental Therapeutics|October 25, 2017
Synergistic Antiproliferative Activity of the RAD51 Inhibitor IBR2 with Inhibitors of Receptor Tyrosine Kinases and Microtubule ProteinPeter J Ferguson, Mark D Vincent, James Koropatnick
Canadian Respiratory Journal|April 25, 2003
Primary chemoradiation as definitive treatment for unresectable cancer of the tracheaGregory M M Videtic, Carolyn Campbell, Mark D Vincent
Expert Review of Pharmacoeconomics & Outcomes Research|April 24, 2018
Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugsGeorge Dranitsaris, Xiaofu Zhu, Georges Adunlin, et al.
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|July 22, 2014
Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic modelCharles H Lineweaver, Paul C W Davies, Mark D Vincent
Pageof 4